News

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

· The Benevolent PlatformTM for AI-driven drug discovery identified and validated a novel biological target not previously linked to the disease


· BenevolentAI researchers nominated preclinical candidate within two years of novel target validation


· Ulcerative Colitis asset rapidly advancing to the clinic alongside biomarker development to identify patients most likely to respond to treatment


London, 14 October, 2021, In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials.

Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis. BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation. The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment.

BenevolentAI plans to move the programme into the clinic in early 2023. The company is currently applying its precision medicine AI models to inform clinical trial design, trained on ulcerative colitis patient data to target key responder patient cohorts and identify efficacy biomarkers.

Anne Phelan, Chief Scientific Officer at BenevolentAI, commented, "Ulcerative colitis is a chronic, lifelong disease that affects 0.2% of the US population alone and 1.6 million patients in the 7 major markets, yet it is poorly served by the standard of care therapies. Our novel preclinical candidate addresses the high unmet need for an oral, safe and efficacious therapy and has demonstrated improved safety and tolerability profile compared with other leading IBD treatments. We are actively using patient-derived molecular descriptors to target patient subgroups that will optimise trial design and further increase our probability of success."

Joanna Shields, Chief Executive Officer of BenevolentAI, commented: "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease.”

This latest milestone in ulcerative colitis further validates Benevolent’s AI Platform and drug discovery expertise in identifying novel targets for complex multifactorial diseases. In early 2021, a novel AI-generated target was selected for AstraZeneca's portfolio in CKD, with further targets expected in IPF. The ulcerative colitis programme sits within a rapidly scaling pipeline of over 20 in-house programmes, including an asset in clinical trials for atopic dermatitis. The company also discovered Eli Lilly’s baricitinib as a treatment for COVID-19 – a novel drug repurposing hypothesis that is now clinically validated and FDA Approved. As of 2021, BenevolentAI is the only AI-augmented drug discovery company whose drug discovery platform and approach has been validated computationally, experimentally and in the clinic.



Media inquiries

Rajin Kang

rajin.kang@benevolent.ai 

About BenevolentAI 

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 20+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.


More Posts

You Might Also Like

News
BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022